{"id":833196,"date":"2022-11-08T18:34:07","date_gmt":"2022-11-08T17:34:07","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/"},"modified":"2022-11-08T18:34:07","modified_gmt":"2022-11-08T17:34:07","slug":"sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/","title":{"rendered":"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress"},"content":{"rendered":"Completion of rolling NDA submission for zuranolone in MDD and PPD on track for December 2022\n\n\nPresented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD\n\n\nCompany appoints Laura Gault, M.D., Ph.D., as Chief Medical Officer, enhancing management team and advancing Sage\u2019s position as a leader in brain health and a top-tier biopharmaceutical company\n\n\nCash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, expected to support operations into 2025\n\nCAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a wor<div class=\"leaky_paywall_message_wrap\"><div id=\"leaky_paywall_message\"><a href=\"https:\/\/bebeez.it\/abbonati\/\">Abbonati<\/a> o <a href=\"https:\/\/bebeez.it\/mio-account\/\">Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Completion of rolling NDA submission for zuranolone in MDD and PPD on track for December 2022 Presented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD Company appoints Laura Gault, M.D., Ph.D., as Chief Medical Officer, enhancing management team and [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-833196","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress - BeBeez\" \/>\n<meta property=\"og:description\" content=\"Completion of rolling NDA submission for zuranolone in MDD and PPD on track for December 2022 Presented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD Company appoints Laura Gault, M.D., Ph.D., as Chief Medical Officer, enhancing management team and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-08T17:34:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress\",\"datePublished\":\"2022-11-08T17:34:07+00:00\",\"dateModified\":\"2022-11-08T17:34:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/\"},\"wordCount\":3288,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/\",\"name\":\"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-11-08T17:34:07+00:00\",\"dateModified\":\"2022-11-08T17:34:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/","og_locale":"en_US","og_type":"article","og_title":"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress - BeBeez","og_description":"Completion of rolling NDA submission for zuranolone in MDD and PPD on track for December 2022 Presented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD Company appoints Laura Gault, M.D., Ph.D., as Chief Medical Officer, enhancing management team and [&hellip;]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/","og_site_name":"BeBeez","article_published_time":"2022-11-08T17:34:07+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/"},"author":{"name":"","@id":""},"headline":"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress","datePublished":"2022-11-08T17:34:07+00:00","dateModified":"2022-11-08T17:34:07+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/"},"wordCount":3288,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/","name":"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-11-08T17:34:07+00:00","dateModified":"2022-11-08T17:34:07+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/sage-therapeutics-announces-third-quarter-2022-financial-results-and-highlights-pipeline-and-business-progress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/833196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=833196"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/833196\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=833196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=833196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=833196"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=833196"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=833196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}